Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators.
about
Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacksAnticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutterAnticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attackProtocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN893Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysisSystematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillationLong term anticoagulation or antiplatelet treatment. Only warfarin has been shown to reduce stroke risk in patients with atrial fibrillation.Atrial fibrillation and stroke preventionPrevention of ischaemic stroke.Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs.Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks.Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.Anticoagulant use in nonvalvular atrial fibrillation. Determining risk and choosing the safest course.Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.Inhibitors of platelet signal transduction as anti-aggregatory drugs.Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation.Antithrombotic therapy in cardiac embolism.Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studiesDevelopment of a decision aid for atrial fibrillation who are considering antithrombotic therapySystematic review of observational studies assessing bleeding risk in patients with atrial fibrillation not using anticoagulants.Antithrombotic medication for cardioembolic stroke preventionBaseline characteristics in stroke patients with atrial fibrillation: clinical trials versus clinical practice.Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Preventing stroke in atrial fibrillation patients - clinical utility of oral anticoagulants.Exploratory Network Meta Regression Analysis of Stroke Prevention in Atrial Fibrillation Fails to Identify Any Interactions with Treatment Effect.The use of antithrombotics in patients presenting with stroke and atrial fibrillationFrequency of adverse events in patients with poor anticoagulation: a meta-analysisAtrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms.Advancement in antithrombotics for stroke prevention in atrial fibrillation.Antithrombotic therapy for the treatment of atrial fibrillation in the elderly.The business case for quality improvement: oral anticoagulation for atrial fibrillation.Stroke prevention in atrial fibrillation patients.Recent advances in oral anticoagulation for atrial fibrillation.Emerging antiplatelet agents, differential pharmacology, and clinical utility.Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice.Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W.Atrial Fibrillation: Defining Some Unanswered Questions.Stroke: secondary prevention.Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation.
P2860
Q24244298-3080EFF9-AEE4-4774-B1B8-96BB1793C1A9Q24245613-75C8000F-2AA5-4705-922F-B53DA0E07E49Q24245863-AC0EF4BD-5EA8-4231-8C35-9422D405CA5BQ24801915-F7293EBD-0C10-4D80-A04E-C432E6A01C10Q28081598-4D0445BC-E1DE-45F1-A241-D25BF10672A4Q28175307-81488271-D89A-4152-A01C-4568EA7E459BQ28187842-6BAA2544-801B-478A-8993-0883748CDC4DQ28201536-3EB040FB-FD28-425E-8465-19009D48A709Q33803258-19925F56-B445-46A9-A3EF-1AD04CACAE93Q33815844-6EEC610C-57E8-486B-A7A7-694FD9FE5BBBQ33891646-FD4FC729-6633-4326-9DAA-FD4E71E98200Q33907713-B068C795-A74B-47F4-B2A3-305AB1F809B4Q33908359-69D213D4-147B-44D6-B7A8-FB83FC5658BAQ34010271-1DFB4A4D-AA5B-457C-B9E3-A8EFE6BBAAAEQ34202452-21425353-01A0-4CD9-9FBC-07AF75B9CC54Q34232030-B6B7C787-1471-4C26-92E5-1E8C9390A9BCQ34233473-10D7AD22-A3CA-4503-B4AF-A8899A3F17C0Q34362901-788939A1-A742-4EC2-9154-B8EC3202542EQ34585334-538CC011-D840-4420-9EEC-1D08AFF677B4Q34746642-D780ADA3-EA99-42BF-B1B9-A8A24E2C78AFQ35093560-D20B6348-8DAC-445B-BA6B-3E2C75EA7E37Q35142419-6ED30F2A-785F-4E0D-A3F1-18B1B8CF8A04Q35673546-D82FF509-37D2-478B-9182-639FC772CB51Q35752573-21AD9BB5-C4FB-4E35-B9CB-9E7566BD3F5AQ35938914-0F657149-A86D-4AE7-AF50-01AD843E89C4Q36112764-B13C1E84-FC6D-4486-AE74-5D1C473A9BC2Q36661298-BF3EF791-F9C1-41D2-BA6C-F38BE357454DQ36827674-584E540C-3D80-4063-9890-EBBA7746BAB6Q36956791-4C0D6857-BDEE-4539-885E-AA3B8DF0C7B4Q37143256-29A97AD7-D961-439D-8C1E-332FC272464AQ37369998-7AF83045-719C-44EE-9A77-6BAB615B5D4FQ37666333-F4E840A1-CD99-4A1E-B539-5B5F9DE6737EQ37780750-8D7C9CAE-F6A0-42E9-8E13-FA9D9DF6B61AQ37802084-73955169-BB90-4F30-BE7F-0E8567DED308Q37979178-52301B11-6D1D-4D15-8A31-C22D7CB83EBFQ38935753-369C44D4-C532-462F-9314-744D0FEF467DQ39850461-BDCEF3CD-F36C-4B9A-843E-E2ECE8F26714Q41720881-F30DBF2A-E9CB-4050-8905-92E198548C6AQ46722175-B6D8DE9F-D938-4BFD-91DC-4C2A20E38E0FQ55312336-2D7F3DF7-6C7C-4A13-8146-A10D7F9869F2
P2860
Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Indobufen versus warfarin in t ...... azione Atriale) Investigators.
@en
Indobufen versus warfarin in t ...... atic atrial fibrillation. SIFA
@nl
type
label
Indobufen versus warfarin in t ...... azione Atriale) Investigators.
@en
Indobufen versus warfarin in t ...... atic atrial fibrillation. SIFA
@nl
prefLabel
Indobufen versus warfarin in t ...... azione Atriale) Investigators.
@en
Indobufen versus warfarin in t ...... atic atrial fibrillation. SIFA
@nl
P2093
P356
P1433
P1476
Indobufen versus warfarin in t ...... azione Atriale) Investigators.
@en
P2093
A Nicolosi
C Morocutti
F Fattapposta
F Pamparana
G Milanesi
M Lavezzari
M Trappolini
S Coccheri
P304
P356
10.1161/01.STR.28.5.1015
P407
P577
1997-05-01T00:00:00Z